[1] Alberio T, Fasano M. Proteomics in Parkinson's disease: An unbiased approach towards peripheral biomarkers and new therapies[J]. J Biotechnol, 2010, 156 (4):325-337.[2] Braak H, Ghebremedhin E, Rüb U, et al. Stages in the development of Parkinson's disease-related pathology[J]. Cell Tissue Res, 2004, 318 (1):121-134.[3] Klos K J, Ahlskog J E, Josephs K A, et al. Alpha-synuclein pathology in the spinal cords of neurologically asymptomatic aged individuals[J]. Neurology, 2006, 66 (7):1100-1102.[4] Cersosimo M G, Benarroch E E. Neural control of the gastrointestinal tract: implications for Parkinson disease[J]. Mov Disord, 2008, 23(8):1065-1075.[5] Paleologou K E, Kragh C L, Mann D M, et al. Detection of elevated levels of soluble alpha-synuclein oligomers in post-mortem brain extracts from patients with dementia with Lewy bodies[J]. Brain, 2009, 132(Pt 4):1093-1101.[6] El-Agnaf O M, Salem S A, Paleologou K E, et al. Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease[J]. FASEB J, 2006, 20(3):419-425.[7] 李雁, 殷娟娟, 李昕, 等.α-突触核蛋白寡聚体对多巴胺能神经细胞线粒体膜电位的影响[J].中国现代神经疾病杂志, 2008, 8:26-31.[8] Ono K, Noguchi-Shinohara M, Yoshita M, et al. Cerebrospinal fluid of Alzheimer's disease and dementia with Lewy bodies patients enhances alpha-synuclein fibril formation in vitro[J]. Exp Neurol, 2007, 203(2):579-583.[9] Ilic T V, Jovanovic M, Jovicic A, et al. Oxidative stress indicators are elevated in de novo Parkinson's disease patients[J]. Funct Neurol, 1999, 14(3):141-147.[11] 程芙蓉, 李昕, 殷娟娟, 等.过氧化氢和帕金森病患者血清促进α-突触核蛋白向线粒体与细胞核转运[J].首都医科大学学报, 2010, 31(6):732-736.[10] Dexter D T, Carter C J, Wells F R, et al. Basal lipid peroxidation in substantia nigra is increased in Parkinson's disease[J]. J Neurochem, 1989, 52(2):381-389.[12] Prakash K M, Tan E K. Development of Parkinson's disease biomarkers[J]. Expert Rev Neurother, 2010, 10(12):1811-1825.[13] Lee P H, Lee G, Park H J, et al. The plasma alpha-synuclein levels in patients with Parkinson's disease and multiple system atrophy[J]. J Neural Transm, 2006, 113(10):1435-1439.[14] Duran R, Barrero F J, Morales B, et al. Plasma alpha-synuclein in patients with Parkinson's disease with and without treatment[J]. Mov Disord, 2010, 25(4):489-493.[15] Bruggink K A, Kuiperij H B, Ekholm-Pettersson F, et al. Detection of elevated levels of α-synuclein oligomers in CSF from patients with Parkinson disease[J]. Neurology, 2011, 77(5):510-511. |